We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Julie Brahmer, MD, director of thoracic oncology and ...
The approval was based on a cohort of treatment-naïve patients in the Beamion LUNG-1 trial who had unresectable or metastatic, non-squamous NSCLC with HER2 tyrosine kinase domain mutations.
The FDA has granted accelerated approval to zongertinib (Hernexeos; Boehringer Ingelheim Pharmaceuticals, Inc.) for adults with unresectable or metastatic non-squamous non–small cell lung cancer ...
Giredestrant Giredestrant (GIRE), an oral selective oestrogen receptor (ER) antagonist and degrader, + everolimus (E) in patients (pts) with ER-positive, HER2-negative advanced breast cancer (ER+, ...
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Dec. 05, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (ORIC), a clinical stage oncology company focused on developing treatments that address ...
If you or a loved one has lung cancer, you may be looking into treatment options. A new medicine you might hear about is Hernexeos (zongertinib). More specifically, Hernexeos is FDA-approved to treat ...
Our conference coverage featured updates on clinical trials testing new treatments for NSCLC, bladder cancer, and breast cancer. Highlights of the conference coverage from the 2025 European Society of ...
In conjunction with the ESMO Asia Congress, ORIC will host a conference call and webcast on Saturday, December 6, 2025, at 8:00 pm ET. To join the conference call via phone and participate in the live ...
The oral targeted therapy sevabertinib led to tumor reduction and manageable side effects in patients with HER2-mutant non-small cell lung cancer (NSCLC), according to data from a trial led by ...
Lunit’s SCOPE IO artificial intelligence (AI)-based pathology platform has demonstrated its ability to generate biomarkers that predict patients’ response to immunotherapy across cancer types. Data ...
Eyes will be on Eikon’s upcoming data readout for its toll-like receptors 7 and 8 (TLR7/8) co-agonist, as the company looks to buck the trend of recent clinical trial failures with candidates that ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results